2023
Absence of either Ripk3 or Mlkl reduces incidence of hepatocellular carcinoma independent of liver fibrosis
Mohammed S, Thadathil N, Ohene-Marfo P, Tran A, Van Der Veldt M, Georgescu C, Oh S, Nicklas E, Wang D, Haritha N, Luo W, Janknecht R, Miller B, Wren J, Freeman W, Deepa S. Absence of either Ripk3 or Mlkl reduces incidence of hepatocellular carcinoma independent of liver fibrosis. Molecular Cancer Research 2023, 21: 933-946. PMID: 37204757, PMCID: PMC10472095, DOI: 10.1158/1541-7786.mcr-22-0820.Peer-Reviewed Original ResearchConceptsNonalcoholic fatty liver diseaseProgression of NAFLDHepatocellular carcinomaChronic inflammationLiver fibrosisMale miceMouse modelCholine-deficient high-fat dietFemale wild-type miceOncogenic pathwaysFatty liver diseaseMarkers of inflammationHigh-fat dietLow-fat dietDevelopment of inflammationValid therapeutic targetWild-type miceHepatic inflammationInflammation contributesLiver diseaseWT miceFemale miceSex-specific differencesInflammationTherapeutic target
2022
17α-estradiol, a lifespan-extending compound, attenuates liver fibrosis by modulating collagen turnover rates in male mice
Ali Mondal S, Sathiaseelan R, Mann S, Kamal M, Luo W, Saccon T, Isola J, Peelor F, Li T, Freeman W, Miller B, Stout M. 17α-estradiol, a lifespan-extending compound, attenuates liver fibrosis by modulating collagen turnover rates in male mice. AJP Endocrinology And Metabolism 2022, 324: e120-e134. PMID: 36516471, PMCID: PMC9902223, DOI: 10.1152/ajpendo.00256.2022.Peer-Reviewed Original ResearchConceptsLiver fibrosisMale miceCombination hormone replacement therapyMatrix metalloproteinase-2 activityHepatic stellate cell activationChronic liver diseaseHormone replacement therapySubset of womenMetalloproteinase-2 activityStellate cell activationGrowth factor-β1Proinflammatory macrophage activationFibrotic burdenCollagen synthesis ratesChronic treatmentLiver diseaseReplacement therapyCytokine expressionMacrophage contentImmune cellsTGF-β1Estrogen signalingHSC activationFactor-β1Macrophage activation
2021
NUTM1-Rearranged Neoplasms—A Heterogeneous Group of Primitive Tumors with Expanding Spectrum of Histology and Molecular Alterations—An Updated Review
Luo W, Stevens T, Stafford P, Miettinen M, Gatalica Z, Vranic S. NUTM1-Rearranged Neoplasms—A Heterogeneous Group of Primitive Tumors with Expanding Spectrum of Histology and Molecular Alterations—An Updated Review. Current Oncology 2021, 28: 4485-4503. PMID: 34898574, PMCID: PMC8628659, DOI: 10.3390/curroncol28060381.Peer-Reviewed Original ResearchConceptsGenome-wide histone modificationsPost-meiotic spermatidsExpression of oncogenesTumor suppressor geneTranscription regulationHistone modificationsBromodomain proteinsNuclear proteinsRNA sequencingFusion proteinProtein productsSuppressor geneFusion partnerGenesSitu hybridizationDifferent clinical coursesProteinSkin adnexal tumorsPrimitive morphologyOncogenic driversInhibitor therapyClinical courseMolecular alterationsPrimitive tumorHematologic malignanciesCombined ASBT Inhibitor and FGF15 Treatment Improves Therapeutic Efficacy in Experimental Nonalcoholic Steatohepatitis
Matye D, Wang H, Luo W, Sharp R, Chen C, Gu L, Jones K, Ding W, Friedman J, Li T. Combined ASBT Inhibitor and FGF15 Treatment Improves Therapeutic Efficacy in Experimental Nonalcoholic Steatohepatitis. Cellular And Molecular Gastroenterology And Hepatology 2021, 12: 1001-1019. PMID: 33965587, PMCID: PMC8346663, DOI: 10.1016/j.jcmgh.2021.04.013.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsBile Acids and SaltsCholesterolCombined Modality TherapyDependovirusDisease Models, AnimalFibroblast Growth FactorsFructoseGene Expression ProfilingGene Expression RegulationGenetic TherapyGenetic VectorsMaleMethylaminesMiceNon-alcoholic Fatty Liver DiseaseThiazepinesTreatment OutcomeConceptsNonalcoholic steatohepatitisBile acid synthesisTherapeutic efficacyFGF19 analogueASBT inhibitorTreatment-associated adverse eventsFecal bile acid excretionASBT inhibitionDiet-induced nonalcoholic steatohepatitisHepatic bile acid synthesisWeight lossBile acid excretionGrowth factor 15Experimental nonalcoholic steatohepatitisDiet-fed miceFurther clinical studiesNew treatment strategiesIntestinal lipid absorptionAdverse eventsAdipose inflammationMetabolic improvementTreatment attenuatesLipid malabsorptionClinical findingsTreatment strategiesAn integrated model of N6-methyladenosine regulators to predict tumor aggressiveness and immune evasion in pancreatic cancer
Zhou Z, Zhang J, Xu C, Yang J, Zhang Y, Liu M, Shi X, Li X, Zhan H, Chen W, McNally L, Fung K, Luo W, Houchen C, He Y, Zhang C, Li M. An integrated model of N6-methyladenosine regulators to predict tumor aggressiveness and immune evasion in pancreatic cancer. EBioMedicine 2021, 65: 103271. PMID: 33714027, PMCID: PMC7966986, DOI: 10.1016/j.ebiom.2021.103271.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsPancreatic ductal adenocarcinomaImmune evasionCheckpoint inhibitorsOverall survivalImmune infiltrationPancreatic cancerTumor aggressivenessM6A regulatorsSomatic copy number alterationsT cell exhaustionDismal overall survivalMutation profilesN6-methyladenosine regulatorsHigh response ratePancreatic cancer prognosisClassical pancreatic ductal adenocarcinomaCancer CenterColorectal cancerTumor recurrenceDuctal adenocarcinomaM6AscoreBreast cancerTreatment responseCell exhaustion
2020
Genomic and single cell sequencing facilitate the dissection of heterogeneity of pancreatic tumors
Edil B, Luo W, Li M. Genomic and single cell sequencing facilitate the dissection of heterogeneity of pancreatic tumors. BMC Medicine 2020, 18: 177. PMID: 32635908, PMCID: PMC7341579, DOI: 10.1186/s12916-020-01637-3.Peer-Reviewed Original ResearchGastrointestinal Injury Related to Antiangiogenesis Cancer Therapy
Tang T, Abu-Sbeih H, Ma W, Lu Y, Luo W, Foo W, Richards D, Halperin D, Ge P, Wang Y. Gastrointestinal Injury Related to Antiangiogenesis Cancer Therapy. Clinical Colorectal Cancer 2020, 19: e117-e123. PMID: 32284253, DOI: 10.1016/j.clcc.2020.03.002.Peer-Reviewed Original ResearchConceptsAbnormal endoscopic findingsAntiangiogenesis cancer therapyIntensive care unitAntiangiogenesis therapyACD symptomsAntimotility agentsEndoscopic findingsColonic perforationCare unitTertiary care cancer centerActive histologic inflammationRare adverse eventsCancer therapyEnterocolitis symptomsHistologic inflammationNonulcerative inflammationUnderlying malignancyGastrointestinal injuryGastrointestinal toxicityMucosal ulcerationUnderwent endoscopyAdverse eventsMedian durationMost patientsEndoscopic evaluationNeutropenic Enterocolitis: Clinical Features and Outcomes.
Abu-Sbeih H, Ali F, Chen E, Mallepally N, Luo W, Lu Y, Foo W, Qiao W, Okhuysen P, Adachi J, Hachem R, Altan M, Jenq R, Wang Y. Neutropenic Enterocolitis: Clinical Features and Outcomes. Diseases Of The Colon & Rectum 2020, 63: 381-388. PMID: 31842164, DOI: 10.1097/dcr.0000000000001548.Peer-Reviewed Original ResearchConceptsMD Anderson Cancer CenterNeutropenic enterocolitisGranulocyte colony-stimulating factorAnderson Cancer CenterCancer CenterColony-stimulating factorMucosal injuryClinical featuresSurvival rateTexas MD Anderson Cancer CenterConcomitant systemic infectionImmunosuppressive therapy useDuration of neutropeniaRetrospective cohort studyAbsolute neutrophil countCox regression analysisComprehensive cancer centerLower survival rateAbdominal symptomsEnterocolitis diagnosisEnterocolitis symptomsNeutropenia onsetPneumatosis intestinalisCohort studyColonic perforation
2019
Gastrointestinal Adverse Events Observed After Chimeric Antigen Receptor T-Cell Therapy
Abu-Sbeih H, Tang T, Ali F, Luo W, Neelapu S, Westin J, Okhuysen P, Foo W, Curry J, Richards D, Ge P, Wang Y. Gastrointestinal Adverse Events Observed After Chimeric Antigen Receptor T-Cell Therapy. American Journal Of Clinical Oncology 2019, 42: 789-796. PMID: 31478934, DOI: 10.1097/coc.0000000000000596.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge DistributionAntineoplastic Combined Chemotherapy ProtocolsAsparaginaseBiopsy, NeedleCohort StudiesCytarabineDaunorubicinFemaleGastric MucosaGastritisGastrointestinal DiseasesHematologic NeoplasmsHumansImmunohistochemistryImmunotherapy, AdoptiveIncidenceMaleMiddle AgedPrognosisReceptors, Chimeric AntigenRetrospective StudiesRisk AssessmentSeverity of Illness IndexSex DistributionThioguanineConceptsChimeric antigen receptor T-cell therapyCytokine release syndromeGastrointestinal adverse eventsGI AEsT-cell therapyRefractory colitisEncephalopathy syndromeRelease syndromeAdverse eventsHematologic malignanciesDiffuse large B-cell lymphomaLarge B-cell lymphomaGastrointestinal tract inflammationGrade 1 diarrheaOnly symptomatic treatmentStandard of careCertain hematologic malignanciesB-cell lymphomaCART infusionAbdominal distensionAbdominal painBloody stoolGastrointestinal symptomsMedian durationExperienced diarrheaUpper gastrointestinal symptoms and associated endoscopic and histological features in patients receiving immune checkpoint inhibitors
Tang T, Abu-Sbeih H, Luo W, Lum P, Qiao W, Bresalier R, Richards D, Wang Y. Upper gastrointestinal symptoms and associated endoscopic and histological features in patients receiving immune checkpoint inhibitors. Scandinavian Journal Of Gastroenterology 2019, 54: 538-545. PMID: 31079556, DOI: 10.1080/00365521.2019.1594356.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsUpper GI symptomsRisk factorsGI symptomsCheckpoint inhibitorsGI inflammationAnti-PD-1/L1Non-steroidal anti-inflammatory drugsUpper GI injuryUpper GI toxicityGastrointestinal adverse eventsUpper gastrointestinal symptomsProton pump inhibitorsLower GI tractAnti-inflammatory drugsRate of ulcerationGI injuryICI initiationDuodenal involvementEndoscopic evidenceGastrointestinal symptomsGI toxicityImmunosuppressive therapyAdverse eventsGastric involvementAcute liver injury in the context of immune checkpoint inhibitor-related colitis treated with infliximab
Zhang H, Luo W, Wang Y. Acute liver injury in the context of immune checkpoint inhibitor-related colitis treated with infliximab. Journal For ImmunoTherapy Of Cancer 2019, 7: 47. PMID: 30777137, PMCID: PMC6380028, DOI: 10.1186/s40425-019-0532-1.Peer-Reviewed Original ResearchConceptsImmune-related adverse reactionsGrade 3 colitisGastrointestinal reactionsLiver injuryClinical historyImmune checkpoint inhibitor-related colitisBackgroundImmune checkpoint inhibitorsElevated liver enzymesPD-1 inhibitorsTNF-α agentsAcute liver injuryInflammatory bowel diseaseOne-time infusionInfliximab therapyAcute hepatitisCheckpoint inhibitorsRescue therapyAdvanced malignanciesBiologic agentsBowel diseaseLiver profileCase presentationWePatient populationCTLA-4Final diagnosisGastroesophageal junction Paneth cell carcinoma with extensive cystic and secretory features – case report and literature review
Luo W, Hofstetter W, Tan D. Gastroesophageal junction Paneth cell carcinoma with extensive cystic and secretory features – case report and literature review. Diagnostic Pathology 2019, 14: 1. PMID: 30621725, PMCID: PMC6323739, DOI: 10.1186/s13000-018-0775-z.Peer-Reviewed Original ResearchConceptsNeoplastic Paneth cellsGastroesophageal junctionCell carcinomaPaneth cellsImmunohistochemical stainsProton pump inhibitor therapySubsequent endoscopic mucosal resectionHER2/neu statusBeta-catenin pathwayUpper gastrointestinal bleedingDiagnosis of adenocarcinomaEndoscopic mucosal resectionHER2/neuPeculiar histologic featuresDistinct staining patternsGastrointestinal bleedingCase presentationAInhibitor therapyClinical courseMucosal resectionHistologic featuresBarrett's esophagusEmergency roomTypical adenocarcinomaSecretory changes
2018
Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor–induced colitis: a multi-center study
Abu-Sbeih H, Ali F, Alsaadi D, Jennings J, Luo W, Gong Z, Richards D, Charabaty A, Wang Y. Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor–induced colitis: a multi-center study. Journal For ImmunoTherapy Of Cancer 2018, 6: 142. PMID: 30518410, PMCID: PMC6280383, DOI: 10.1186/s40425-018-0461-4.Peer-Reviewed Original ResearchConceptsMean durationImmune checkpoint inhibitor-induced colitisCheckpoint inhibitor-induced colitisImmune checkpoint inhibitor treatmentAbnormal endoscopic findingsActive histologic inflammationCheckpoint inhibitor treatmentClinical success rateRetrospective case seriesGood safety profileFeatures of chronicityMulti-center studyEndoscopic remissionHistologic inflammationHistologic remissionICI therapyNonulcerative inflammationSteroid therapyVedolizumab infusionsVedolizumab therapyClinical remissionMicroscopic colitisMucosal ulcerationSystemic immunosuppressionAdvanced malignanciesImportance of endoscopic and histological evaluation in the management of immune checkpoint inhibitor-induced colitis
Abu-Sbeih H, Ali F, Luo W, Qiao W, Raju G, Wang Y. Importance of endoscopic and histological evaluation in the management of immune checkpoint inhibitor-induced colitis. Journal For ImmunoTherapy Of Cancer 2018, 6: 95. PMID: 30253811, PMCID: PMC6156850, DOI: 10.1186/s40425-018-0411-1.Peer-Reviewed Original ResearchConceptsEndoscopic featuresClinical outcomesHistologic featuresGrade 3Immune checkpoint inhibitor-induced colitisCheckpoint inhibitor-induced colitisLogistic regressionActive histologic inflammationActive histological inflammationBackgroundImmune checkpoint inhibitorsExtensive colonic involvementMore frequent hospitalizationsMore recurrent symptomsHigh-risk featuresMultivariate logistic regressionSuch adverse eventsTime of onsetHistologic inflammationICPI treatmentCheckpoint inhibitorsColonic involvementEndoscopic inflammationHistological inflammationMucosal ulcerationRecurrent symptoms
2017
HuR promotes the molecular signature and phenotype of activated microglia: Implications for amyotrophic lateral sclerosis and other neurodegenerative diseases
Matsye P, Zheng L, Si Y, Kim S, Luo W, Crossman D, Bratcher P, King P. HuR promotes the molecular signature and phenotype of activated microglia: Implications for amyotrophic lateral sclerosis and other neurodegenerative diseases. Glia 2017, 65: 945-963. PMID: 28300326, PMCID: PMC7944581, DOI: 10.1002/glia.23137.Peer-Reviewed Original ResearchConceptsAmyotrophic lateral sclerosisNeurodegenerative diseasesIL-1βLateral sclerosisALS spinal cordMutant SOD1 micePossible therapeutic targetTranscription factor NF-κBLipopolysaccharide-induced IL-1βFactor NF-κBMolecular signaturesRole of HuRLuciferase reporter studiesActivated microgliaProinflammatory factorsSOD1 miceIL-6Inflammatory pathwaysMicroglial migrationImmune cellsSpinal cordChronic activationMicrogliaNF-κBTherapeutic target